[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415541":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":88,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepato-bilio-pancreatic surgery",null,"Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care",[13],"Procedure: Blood sample during surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"biopsy of the hepatic parenchyma","Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care",[18],"Procedure: Taking an additional biopsy",{"label":20,"type":10,"description":21,"interventionNames":22},"Viral chronic infection","Patients with a viral chronic liver disease",[23],"Diagnostic Test: Blood sample during diagnostic test",[25,30,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"PROCEDURE","Blood sample during surgery","During the hepato-bilio-pancreatic surgery, blood is drawn.",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Taking an additional biopsy","As part of the treatment, an additional biopsy is executed and blood is drawn.",[15],[35],"Blood sample during biopsy",{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"DIAGNOSTIC_TEST","Blood sample during diagnostic test","Blood sample as part of the care",[20],[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Thomas BAUMERT, DR","CONTACT","03 68 85 37 03","thomas.baumert@unistra.fr",[48],{"facility":49,"status":50,"city":51,"state":10,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"PU-PH, Directeur de l'UMR_S1110 Unité Inserm d'affiliation : UMR_S1110","RECRUITING","Strasbourg","67000","France","FR",{"type":56,"coordinates":57},"Point",[58,59],7.74553,48.58392,{"lat":59,"lon":58},[62],{"name":63,"role":44,"phone":45,"phoneExt":10,"email":46},"Thomas BAUMERT, Dr",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100415541","constitution-of-a-biological-collection-to-establish-preclinical-translational-models-for-the-study-of-tumors-and-chronic-liver-diseases-100415541",false,"NCT04690972","\"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases\".","LivMOD","Inclusion Criteria:\n\n1. Patients\n\n   * diagnosed with chronic liver disease (viral or not)\n   * diagnosed with at least one liver nodule for which a biopsy is planned as part of the care\n   * for hepatobiliary surgery planned as part of care\n   * for locoregional treatment for HCC is indicated\n2. Patients able to receive and understand information relating to the study and give their written informed consent\n3. Patients affiliated to the French social security system\n\nExclusion Criteria:\n\n1. Minor patients\n2. Patients under legal protection,\n3. Patients subject to legal protection or unable to express their consent,\n4. Patients in a situation of social fragility,\n5. Pregnant or breastfeeding woman,\n6. No signing of informed consent.","ALL","18 Years",{"count":76,"type":77},800,"ESTIMATED","OBSERVATIONAL","Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.",[81,82,83,84,85,86,87],"Chronic Liver Disease and Cirrhosis","Liver Cancer","Non-Alcoholic Fatty Liver Disease","Non-Alcoholic Steatohepatitis","Viral Hepatitis B","Viral Hepatitis C","Viral Hepatitis D",[89,90,91,92,93],"Liver disease","Ex vivo models","Single cell","Biomarkers","Spheroïds","2026-02-10",{"date":96,"type":97},"2026-02-12","ACTUAL",{"date":99,"type":97},"2021-01-14",{"date":101,"type":77},"2029-09-02",{"name":5,"class":6},1]